Gliflozins cut flares in adults with T2DM and gout: study
The benefits of SGLT-2 inhibitors are clear regardless of prior urate-lowering therapy, say researchers.
SGLT-2 inhibitors can cut the rate of recurrent gout flares by a third compared with DPP-4 inhibitors in older adults with type 2 diabetes, suggest results from a large cohort study.
US and Canadian doctors say gliflozins may also reduce the risk of gout-related hospitalisations and MI, with the benefits seen regardless of prior urate-lowering therapy.
